Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 + Carboplatin in Advanced HER2-Expressed Breast Cancer
NCT07047443Phase 2Not yet recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in breast cancer, sponsored by Anhui Provincial Tumor Hospital. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07047443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07047443.